Sun Pharma Supports Sayaw PD
Sun Pharma is partnering with Sayaw PD, Asia’s first dance program specifically created for people diagnosed with Parkinson’s Disease. Led by Novy Bereber, one of the Philippine’s leading international choreographers, and the only Filipino trained directly by David Leventhal of New York’s Mark Morris Dance Group, the Founders of the Dance for PD program, Sayaw PD is creating a community where patients can learn to dance and enjoy themselves in an artistic, social setting.
Sayaw PD is geared towards improving the overall health of patients with PD – their balance, mobility, strength and confidence – and it’s no wonder that Sun Pharma makes the perfect dance partner. We consistently provide the necessary medicines – made widely available in the largest chain drug stores in the country – and are committed to achieving a better quality of life for PD patients. This is a huge opportunity for us, and we can’t wait to see how this unique partnership will help us all dance the night away.
A Profile of Sun Pharma
Sun Pharmaceutical Industries Ltd. is the fourth largest speciality generic pharmaceutical company in the world. We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 100 countries of the world.
Since our beginning in 1983, Sun Pharma has grown to become India’s largest and most valuable pharmaceutical company by market capitalisation with global revenues of over US$ 4 billion. Even as our business has grown from strength to strength organically, we have added new skills or entered new growth areas with the multiple acquisitions we made since the 1990s. Our largest acquisition so far is Ranbaxy Laboratories Limited.
Diversified Speciality & Generics Portfolio
We manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates. Our broad portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams and liquids. Our presence extends across a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.
Our global presence is supported by over 40 manufacturing facilities. India and the US are our predominant markets, accounting for nearly 70% of our revenues. We are the No. 1 pharmaceutical company in India. Our robust brands give us the competitive edge in acute and chronic therapies, hospitals and over-the-counter (OTC) businesses.
In the US, we are leaders in the generic dermatology market with products that are Anti-Fungal, Steroids and prescribed for the treatment of Acne and Actinic Keratosis. We have strong capabilities in developing complex products with a robust pipeline of ANDAs, including high value First-to-File (FTF) opportunities, with several manufacturing units in the US, as well as US FDA approved manufacturing units in India. This gives us the flexibility of manufacturing offshore or in the US.
We have a robust product pipeline and established presence in Europe and high-growth emerging markets like Russia, Romania, South Africa, Brazil and Mexico. Our presence across multiple emerging markets give us the opportunity for cross-selling and better brand-building.
Margaret Maranan, RPh, MBA
Certified Lean Six Sigma Yellow Belt
Cellphone No. 09062504147
Sayaw PD Disclaimer